Prediabetes Market

Prediabetes Market Highlights

The global prediabetes market is expected to cross a value of USD 45.2 billion by the end of 2032. The market was valued at USD 24.2 billion in 2023 and is expected to expand at a CAGR of 6.9% between 2024-2032.

• Over the mid-term, the growing awareness for prediabetes is the primary factor anticipated to drive the global prediabetes market.
• The limited access to healthcare services in several rural areas is a major factor to challenge the market growth.
• The North America prediabetes market is projected to dominate the global market.

Prediabetes Market Outlook

A condition where the blood sugar levels are higher than normal but not enough to be diagnoses as type 2 diabetes, is referred to as prediabetes. People having this disease consider it to be a warning sign for developing type 2 diabetes, resulting in health complications, including heart diseases and stroke.

As per KD Market Insights analysts, the growth of the global prediabetes market can majorly be attributed to the growing awareness related to the disease. The prevalence of prediabetes around the world is increasing rapidly. This is majorly due to sedentary lifestyles, unhealthy dietary habits, obesity, and aging population among others. The United States Centers for Disease Control and Prevention (CDC) reported having 97.6 million people diagnosed with prediabetes for population aged 18 years or older in the United States alone. Novo Nordisk, Valbiotis, and RESVERLOGIX are some of the significant parties in the global market for prediabetes.

                                  Get More Insights on This Report - Request Free Sample PDF

Prediabetes Market Drivers – Analyst’s Observation

According to the analysts at KD Market Insights, some key growth drivers for the global prediabetes market are:

• Increasing Emphasis on Preventive Healthcare: Owing to the increasing prevalence of different types of diseases worldwide, individuals worldwide are rapidly adding emphasis on preventive healthcare. Early diabetes diagnostics as a measure of preventive healthcare, helps to lower the risk of developing type 2 diabetes and the complications associated with it. The early detection of the disease helps healthcare providers to provide medications to treat the health condition of prediabetes and prevent or delay the onset of diabetes.
• Surge in Advancements in Diagnostic Technologies: With the advancements witnessed in the healthcare industry, the diagnosis of diabetes by using different devices and tests, such as blood glucose monitoring devices, glycated hemoglobin (HbA1c) tests, and oral glucose tolerance tests (OGTT), are also improving. Moreover, the growing affordability of these tests would allow individuals to identify prediabetes earlier, creating an ocean of opportunities for market growth.

Which Probable Factors Could Hamper the Growing Prediabetes Market Trend?

As per our KD Market Insights analysis, some of the challenges expected to limit the global market growth of prediabetes are:

• Lack of Awareness for Prediabetes in Several Countries: One of the major factors expected to hinder the growth of the market is the lack of awareness among healthcare providers and the general population for addressing prediabetes.
• Limited Access to Healthcare Services: In several underserved or rural areas, access to healthcare services are usually limited, majorly as a result of geographic barriers, financial constraints, lack of insurance coverage, and cultural barriers among others. Owing to this limited access to healthcare services, the market for prediabetes is significantly impacted.

How is the Global Prediabetes Market Segmented?

Our experts at KD Market Insights have segmented the global prediabetes market as:

What are the Probable Factors Influencing the North America Prediabetes Market Forecast?

The North America prediabetes market is majorly driven by growing prevalence of obesity in the region, followed by the rising awareness and screening programs for diabetes. The U.S. CDC reported that the prevalence of obesity in the United States from 1999-2000 through 2017-March 2020 touched 41.9% up from 30.5%. As efforts to address the obesity epidemic intensify, there is a parallel focus on identifying and managing prediabetes to prevent the onset of type 2 diabetes. On the other hand, there is a growing emphasis on diabetes prevention and early intervention programs in North America, including initiatives aimed at raising awareness about prediabetes and promoting regular screening among at-risk populations, which is also predicted to boost the market growth for prediabetes in North America.

As per our analysts at KD Market Insights, the following five players lead the North America prediabetes market growth:

• Omada Health
• Virta Health
• Lark Health
• Canary Health
• Noom

Which Key Players Top the Global Prediabetes Market Share?

As per our analysts at KD Market Insights, the competitive landscape of global prediabetes market facilitates our readers in identifying their closest competitors. The manufacturers who are associated with prediabetes market are raising their focus on expanding their presence, as well as their market share. The market has also been witnessing an upward movement in the number of collaborations between research institutions and key players, aimed at introducing advanced technologies and innovation of new products. Here is a list of the key players who top the global prediabetes market share:

• Novo Nordisk
• Valbiotis
• RESVERLOGIX
• Caelus Health
• SciMar
• Boston Therapeutics
• Aphaia Pharma
• AstraZeneca
• Bristol-Myers Squibb

What are the Recent Developments Observed in the Prediabetes Market?

Over the years, the experts at KD Market Insights have been observing the recent developments associated with global prediabetes market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

For instance, Nestle Health Science recently announced that it has collaborated with Valbiotis for introducing a dietary supplement, designed especially for people having prediabetes and type-2 diabetes.

Further, Aphaia Pharma shared that its drug candidate for treating prediabetes, known as APH-012, has begun its phase 2 trials.